News

Routine DAT screening may not be as accurate as transcutaneous bilirubin monitoring for ABO-incompatible newborns at risk for HDFN.

Maternal nipocalimab may lower the risk of severe HDFN in newborns without affecting infant growth or development.

Researchers optimized a prenatal RhD blood test for Chinese and East Asian populations, aiming to improve HDFN prevention.

A case report found that red blood cell antibodies in pregnancy rose sharply in the third trimester and were associated with fetal anemia.

Many doctors are following the updated guidelines about the Rh immunoglobulin shot in pregnancy, according to a recent study published in the journal Pregnancy.

Clinically significant RhD-mediated HDFN was uncommon in positive direct antiglobulin test results among some newborns.

IVIG may be a safe and effective alternative to intrauterine transfusion in HDFN, with nipocalimab emerging as a potential new treatment.

New treatments are still urgently needed for severe HDFN, as many high-risk pregnancies result in significant complications.

Infants who receive an exchange transfusion often see their platelet count drop sharply, leaving them at a greater risk of bleeding.

A novel RHD genotyping technology may help to reduce the number of false positives in HDFN, helping to avoid unneeded treatment.